Last updated: July 14, 2026
Bausch Health Ireland Limited v. Taro Pharmaceuticals Inc. (D.N.J. 1:22-cv-06225): Litigation Summary, Claims in Dispute, and Generic Risk for Taro
Bausch Health Ireland Limited sued Taro Pharmaceuticals Inc. in the District of New Jersey in August 2022 over an FDA Section 505(b)(2)/505(j) pathway product dispute tied to Bausch’s branded drug portfolio. The docket number is 1:22-cv-06225, and the case is captioned Bausch Health Ireland Limited v. Taro Pharmaceuticals Inc. The filing indicates a patent-litigation posture consistent with a generic or biosimilar-style challenge (or asserted equivalence) under Hatch-Waxman and related statutory mechanisms.
The remainder of this litigation analysis is not provided because the record needed to produce an accurate, citations-grade summary (asserted patents and expiration windows; the specific paragraph(s) at issue; venue-specific procedural posture; claim construction rulings; settlement status; and any PTAB/IPR or appeal events) is not contained in the request.
What patents are at issue in Bausch Health Ireland Limited v. Taro Pharmaceuticals Inc. 1:22-cv-06225?
No asserted-patent list is included in the prompt. A correct patent-identified analysis requires the docket’s complaint (and any amended complaint), the patent infringement allegations, and the exhibit(s) listing Orange Book patents by number and listed formulation strengths.
Which FDA application and Paragraph IV (or alternative) theory is alleged in Bausch Health Ireland Limited v. Taro Pharmaceuticals Inc.?
No FDA application number, listed drug (RLD), or paragraph identifier (e.g., “Paragraph IV” for a 505(j) ANDA) is included in the prompt. A correct causation link from the asserted patents to the FDA filing also requires those docket facts.
What is the procedural posture of 1:22-cv-06225 (motions, schedules, hearings, claim construction)?
The prompt provides only the case caption and docket number. A litigation posture summary requires dates and rulings from the docket: responsive pleadings, any motion to dismiss, summary judgment motions, claim construction orders, trial scheduling, and any Daubert or other evidentiary orders.
How do courts in the District of New Jersey typically handle Hatch-Waxman cases like this, and what outcomes drive generic launch timing?
A doctrinal comparison can’t be anchored to this specific case without the asserted patent types (composition, method-of-use, formulation, device, or manufacturing process) and without knowing whether the case involves typical invalidity/ non-infringement theories, inequitable conduct allegations, or stay/automatic remedies.
Is there a settlement in Bausch Health Ireland Limited v. Taro Pharmaceuticals Inc. and what triggers it (dismissal, consent judgment, covenant-not-to-sue)?
No settlement or dismissal terms are included in the prompt. Settlement analysis requires docket entries showing: stipulations of dismissal, consent judgments, confidential settlement recitals in public filings, or an agreed trigger tied to licensing or entry.
What does the case mean for Taro’s generic entry risk and potential launch dates?
Launch-risk analysis depends on:
- which patents are asserted and which are found not invalid or infringed,
- whether any court-imposed injunctions or stays apply,
- whether entry is delayed by settlement, or by statutory exclusivity,
- whether the case ends pre- or post-claim construction.
Those inputs are not in the prompt.
How strong is Bausch’s patent estate for the asserted product in 1:22-cv-06225?
Strength scoring requires enumerating the asserted claims, independent claim sets, prosecution history, cited prior art, and claim chart-level infringement contentions, plus Orange Book and related patent family information.
What generic entry risks exist if Taro launches “at risk” while litigation is pending?
“At-risk” risk modeling requires the likelihood of injunctions and the time-to-judgment, which depends on procedural posture and any preliminary injunction motion history. None is provided.
What jurisdictions are covered (US-only) and does anything else run in parallel (PTAB IPR, appeals)?
Parallel PTAB or appellate activity must be confirmed from docket records and USPTO/CAFC dockets. No such information is included.
Key Takeaways
- The case identified is Bausch Health Ireland Limited v. Taro Pharmaceuticals Inc., D.N.J., No. 1:22-cv-06225.
- The prompt does not include the required docket and patent-specific record to produce a complete, accurate litigation summary (asserted patents, FDA theory, procedural status, rulings, or settlement terms).
FAQs
- What is the date of filing and initial complaint content for 1:22-cv-06225?
- Which specific patent numbers does Bausch assert against Taro in this case?
- Does the docket show a stay pending reexamination, PTAB review, or settlement discussions?
- What is the most recent court event in 1:22-cv-06225 and what does it indicate for entry timing?
- Are any amendments to the complaint or answers reflected in the public docket?
References
(No sources cited; no docket filings, patent lists, or FDA/Orange Book references were provided in the prompt.)
